Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aravive, Inc.VSAR · Entity 114535 | Director | December 20, 2017 | December 22, 2017 |
| Inogen IncINGN · Entity 2083 | Director | May 10, 2021 | May 12, 2021 |
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | September 23, 2026 | September 26, 2026 |
| Sientra, Inc.SIEN · Entity 108294 | Director | June 05, 2018 | June 07, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aravive, Inc.
Report date December 20, 2017 · Filed December 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,380 |
Reported balance
After 2017-12-20 transaction · row 1
1 source rowRow 1 · 2017-12-20 · Grant · Acquired 11,200 · Balance 44,380 F1: Represents the grant of restricted stock units that vest 100% on December 20, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest 100% on December 20, 2018.
Inogen Inc
Report date May 10, 2021 · Filed May 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,775 |
Reported balance
After 2021-05-10 transaction · row 1
1 source rowRow 1 · 2021-05-10 · Grant · Acquired 2,754 · Balance 30,775 F1: The reported shares were acquired pursuant to a restricted stock unit award, which shall vest on the earlier of (i) the one-year anniversary of the date of grant, or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant, in each case, subject to the reporting person continuing to be a service provider through the applicable vesting date. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote (2) | 15,218 |
Reported balance
Holding disclosure · report date 2021-05-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 15,218 F2: Shares held directly by Numenor Ventures, L.L.C. The reporting person and his spouse are the managing members of Numenor Ventures, L.L.C. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote (3) | 14,485 |
Reported balance
Holding disclosure · report date 2021-05-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 14,485 F3: Shares held directly by the R. Scott Greer and Michelle Greer Revocable Trust, a trust for the benefit of the Reporting Person and the Reporting Person's spouse, for which the Reporting Person and the Reporting Person's spouse serve as trustees. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were acquired pursuant to a restricted stock unit award, which shall vest on the earlier of (i) the one-year anniversary of the date of grant, or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant, in each case, subject to the reporting person continuing to be a service provider through the applicable vesting date.
F2: Shares held directly by Numenor Ventures, L.L.C. The reporting person and his spouse are the managing members of Numenor Ventures, L.L.C.
F3: Shares held directly by the R. Scott Greer and Michelle Greer Revocable Trust, a trust for the benefit of the Reporting Person and the Reporting Person's spouse, for which the Reporting Person and the Reporting Person's spouse serve as trustees.
NEKTAR THERAPEUTICS
Report date September 23, 2026 · Filed September 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,239 |
Reported balance
After 2026-09-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 2,000 · Balance 22,239 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2: This RSU award vests in full, one year following September 23, 2026. F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $57.66 · Expires 2034-09-22 | Direct | 4,000 |
Reported balance
After 2026-09-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-23 · Grant · Acquired 4,000 · Balance 4,000 F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2: This RSU award vests in full, one year following September 23, 2026.
F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.
Sientra, Inc.
Report date June 05, 2018 · Filed June 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (RSUs)SEC Table I · non-derivative | Direct | 58,773 |
Reported balance
After 2018-06-05 transaction · row 1
1 source rowRow 1 · 2018-06-05 · Grant · Acquired 6,116 · Balance 58,773 F1: The Common Stock underlying this grant of restricted stock will vest on the earlier to occur of: (i) the day prior to the annual meeting of stockholders for the year following the date of grant or (ii) the one (1) year anniversary of the annual meeting of stockholders of the year of grant, subject to continued service as a director of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Common Stock underlying this grant of restricted stock will vest on the earlier to occur of: (i) the day prior to the annual meeting of stockholders for the year following the date of grant or (ii) the one (1) year anniversary of the annual meeting of stockholders of the year of grant, subject to continued service as a director of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 06, 2018 Filed Apr 10, 2018 00:22 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001209191-18-024452 · doc4.xml · derivative · entry 3 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2018-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 00:22 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 30,000 | $92.22 | $2,766,600.00 |
DisclosureSEC source: 0001209191-18-024452 · doc4.xml · nonDerivative · entry 2 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,333 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $90.05 to $94.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 00:22 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 30,000 | $14.26 | $427,800.00 |
DisclosureSEC source: 0001209191-18-024452 · doc4.xml · nonDerivative · entry 1 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 17:00 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 11,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067089 · doc4.xml · nonDerivative · entry 1 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,380 F1 · shares: Represents the grant of restricted stock units that vest 100% on December 20, 2018. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 20:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $21.75 | $0.00 |
DisclosureSEC source: 0001209191-17-053613 · doc4.xml · derivative · entry 2 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: common stock · 22,500 shares Expires 2025-09-18 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2017. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 20:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053613 · doc4.xml · nonDerivative · entry 1 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,333 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 19, 2017. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 19:32 UTC | Sientra, Inc. SIEN · Entity 108294 | GrantCommon Stock | 12,861 | $9.72 | $125,008.92 |
DisclosureSEC source: 0000899243-17-017260 · doc4.xml · nonDerivative · entry 1 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,546 F1 · shares: The common stock underlying this grant of restricted stock will vest on the earlier to occur of: (i) day prior to the annual meeting of stockholders for the year following the date of grant, or (ii) the one-year anniversary of the annual meeting of stockholders of the year of grant, subject to continued service as a director. Read SEC document |
| May 25, 2017 Filed Jun 6, 2017 20:03 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantStock Option (Right to Buy) · Derivative | 6,850 | $0.00 Strike: $15.83 | $0.00 |
DisclosureSEC source: 0001209191-17-038233 · doc4.xml · derivative · entry 2 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,850 Underlying: Common Stock · 6,850 shares Expires 2027-05-24 F2 · derivative.exercise_date: The shares shall vest fully on the earlier of (a) the next annual stockholder meeting held after May 25, 2017 and (b) May 25, 2018. Read SEC document |
| May 25, 2017 Filed Jun 6, 2017 20:03 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 3,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038233 · doc4.xml · nonDerivative · entry 1 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,180 F1 · shares: Represents the grant of restricted stock units that vest fully on the earlier of (a) the next annual stockholder meeting held after May 25, 2017 and (b) May 25, 2018. Read SEC document |
| May 11, 2017 Filed May 12, 2017 17:32 UTC | Inogen Inc INGN · Entity 2083 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $83.30 | $0.00 |
DisclosureSEC source: 0001209191-17-031806 · doc4.xml · derivative · entry 1 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2024-05-10 F1 · derivative.exercise_date: Subject to reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), 1/12th of the total shares subject to the option shall vest monthly, beginning with the first month anniversary after the vesting commencement date, but will vest fully on the date of the next Annual Meeting of the Issuer's stockholders held after the vesting commencement date. The vesting commencement date for this option is May 11, 2017. Read SEC document |
| October 24, 2016 Filed Oct 25, 2016 21:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | PurchaseCommon Stock | 15,000 | $13.50 | $202,500.00 |
DisclosureSEC source: 0000899243-16-032275 · doc4.xml · nonDerivative · entry 1 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,333 Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 21:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001209191-16-142664 · doc4.xml · derivative · entry 2 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2024-09-20 F3 · derivative.exercise_date: This option vests in equal monthly installments over the one-year period beginning on September 30, 2016. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 21:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142664 · doc4.xml · nonDerivative · entry 1 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,333 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 21, 2016. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:14 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142022 · doc4.xml · derivative · entry 2 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F1 · derivative.exercise_date: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F1 · derivative.expiration_date: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:14 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142022 · doc4.xml · nonDerivative · entry 1 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F2 · balance_after: The total holdings includes the 15,000 shares of restricted stock units ("RSUs") that were previously reported in Table II for the reporting person and which are being reclassified to Table I. These RSUs were granted on September 15, 2015, are convertible on a one-for-one basis into shares of Common Stock of the Company, and vested on September 15, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.